FDA-cleared profile

Arterys Cardio DL

ARTERYS INC. · MRI · FDA-cleared (510(k))

Authorized purpose: Web-accessible post-processing for viewing and quantifying cardiovascular MR images in DICOM format.

Clinical role
Web-accessible post-processing software for viewing and quantifying cardiovascular MR images, based on manual and semi-automatic border detection; results display in the web browser, users can send data to a clinician database such as PACS, and the data support clinical decision-making.
Images and patients
MRI · Heart/Cardiovascular
Key limitation
Keep in mind: Support tool only; not medical advice or a treatment recommendation, with bounded field-strength and acquisition-protocol scope.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Web-accessible post-processing for viewing and quantifying cardiovascular MR images in DICOM format.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Heart/Cardiovascular Input: DICOM-compliant multi-slice, multi-phase, velocity-encoded MR images at 1.5T or 3.0T.
  • Who uses it?Intended users: Qualified cardiologists, radiologists, or other licensed healthcare practitioners.
  • What does the software produce?Output: Cardiac function, flow, segmentation, distance and area measurements, annotated images, browser display, and optional PACS or database transfer.
  • What is its most important limitation?Key limitation: Support tool only; not medical advice or a treatment recommendation, with bounded field-strength and acquisition-protocol scope.

Clinical takeaway. Clinical role: Web-accessible post-processing for viewing and quantifying cardiovascular MR images in DICOM format.

Evidence takeaway. Evidence from the reviewed source record: Software verification and validation under IEC 62304 and FDA software and cybersecurity guidance; no numeric clinical study was reported in the summary.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Web-accessible post-processing for viewing and quantifying cardiovascular MR images in DICOM format.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Web-accessible post-processing software for viewing and quantifying cardiovascular MR images, based on manual and semi-automatic border detection; results display in the web browser, users can send data to a clinician database such as PACS, and the data support clinical decision-making.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Arterys Cardio DL is a web-accessible image post-processing analysis software device used for viewing and quantifying cardiovascular MR images. The device is intended to visualize and quantify MRI data in DICOM format. Manual and semi-automatic border detection forms the basis for analysis." … "are displayed to the user within the software client web browser. The user has the option to save the data for later use. The user can also send the data to the clinician database, such as PACS, for review.". Read from the exact FDA decision document on 2026-11-14.

Required input
DICOM-compliant multi-slice, multi-phase, velocity-encoded MR images at 1.5T or 3.0T.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet acquisition scope.

Output and clinician action
Cardiac function, flow, segmentation, distance and area measurements, annotated images, browser display, and optional PACS or database transfer.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet output scope.

Care setting
Adult and Pediatric
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Qualified cardiologists, radiologists, or other licensed healthcare practitioners.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet intended-user statement.

Limitations
Support tool only; not medical advice or a treatment recommendation, with bounded field-strength and acquisition-protocol scope.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA limitation boundary.

Evidence summary
Software verification and validation under IEC 62304 and FDA software and cybersecurity guidance; no numeric clinical study was reported in the summary.
  • Exact FDA submission
  • Checked 2026-09-15

Packet testing description, not independent clinical validation.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Software verification and validation under IEC 62304 and FDA software and cybersecurity guidance; no numeric clinical study was reported in the summary.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Packet testing description, not independent clinical validation.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K163253. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM-compliant multi-slice, multi-phase, velocity-encoded MR images at 1.5T or 3.0T.

    Scope: Exact FDA submission. FDA packet acquisition scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K163253: Arterys Cardio DL

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · Arterys Cardio DL model card (K163253)

  3. AI processing

    Source context, not route validation: The exact FDA package describes Arterys Cardio DL as web-accessible post-processing software on a client-server, Chrome desktop platform, with results displayed within the software client web browser. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Arterys Cardio DL is a web-accessible image post-processing analysis software device used for viewing and quantifying cardiovascular MR images." … "The distance, area, volume, and blood flow statistics, along with user-selected, annotated images, are displayed to the user within the software client web browser.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K163253: Arterys Cardio DL

  4. Returned objects

    Source context, not route validation: Cardiac function, flow, segmentation, distance and area measurements, annotated images, browser display, and optional PACS or database transfer.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K163253: Arterys Cardio DL

  5. Viewer/worklist/report

    Unresolved route: Cardiac function, flow, segmentation, distance and area measurements, annotated images, browser display, and optional PACS or database transfer.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K163253: Arterys Cardio DL

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Arterys Cardio DL as web-accessible post-processing software on a client-server, Chrome desktop platform, with results displayed within the software client web browser. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Arterys Cardio DL is a web-accessible image post-processing analysis software device used for viewing and quantifying cardiovascular MR images." … "The distance, area, volume, and blood flow statistics, along with user-selected, annotated images, are displayed to the user within the software client web browser.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Security
Tempus's responsible disclosure policy commits to vulnerability intake for any of its assets (tempus.com and public internet-facing and cloud infrastructure it operates), coordinated handling with a 90-day disclosure window, timely correction, and a safe-harbor commitment for good-faith research. Arterys' own site states Arterys has joined Tempus as Tempus Radiology.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement. Entity bridge: arterys.com announces 'Arterys has joined Tempus... as Tempus Radiology'. The Tempus policy is an organizational vulnerability-handling statement; no certification or audit report was read, and exact-release scope is not established. Applicant name variant 'ARTERYS INC.' is bridged to Arterys, Inc. via the identical distinctive name and Arterys product naming.

Monitoring
Tempus' responsible disclosure policy, covering Tempus assets and operated infrastructure, states vulnerability intake with a 90-day coordinated disclosure window and a timely correction commitment.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The policy names Tempus generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS is explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Arterys Cardio DL; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K163253
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet cardiovascular MR scope.

Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet covers heart and major vessels.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2017-01-05
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K163253 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K163253: Arterys Cardio DL

    U.S. Food and Drug Administration - Published 2017-01-05 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Arterys Cardio DL model card (K163253)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, integration, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K163253

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Tempus: Responsible Disclosure Policy

    Tempus Labs - Accessed 2026-10-27

    Scope: security

Research history

  1. K163253 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252084

AI4CMR v2.0

Ai4medimaging Medical Solutions S.A.

Authorized purpose: Cardiac MRI ventricular function and 2D phase-contrast flow quantification

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2026-02-11
FDA-cleared K241922

Myomics

Phantomics Inc.

Authorized purpose: Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including heart and adjacent-vessel measurements; semi-automated machine-learning workflows are intended for adults and contribute to comprehensive diagnostic decision-making.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2025-02-28
FDA-cleared K223523

Sonic DL

GE Medical Systems,LLC (GE Healthcare)

Sonic DL is deep-learning MRI reconstruction for highly undersampled or accelerated cardiac acquisitions on compatible GE 1.5T and 3.0T MRI systems for pediatric and adult patients.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2023-05-30
FDA-cleared K183274

RTHawk, HeartVista Cardiac Package

HeartVista, Inc.

Accessory acquisition, reconstruction, and display of cardiovascular MR images on compatible 1.5T and 3T whole-body MRI systems for trained-physician interpretation.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2019-10-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history